Multiple Sclerosis Resource Centre

Welcome to the Multiple Sclerosis Resource Centre. This website is intended for international healthcare professionals with an interest in Multiple Sclerosis. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Interview with Mark Cascione at ECTRIMS 2015: Design and results of the PRISM study

CASCIONE-HD

In the first 2 years of the study, patients with RRMS (relapsing remitting multiple sclerosis) were given randomised treatment with 22 or 44 µg rebif [interferon beta 1-a], or placebo. In the second 2 years of the study, the placebo patients were treated with 22 or 44 µg rebif. In a retrospective analysis, the predictive value of the following factors were investigated for disability progression at 2 or 4 years:

  1. Did the patient have disability progression during the first 6 months of treatment?
  2. Did the patient suffer at least one clinical relapse during the first 6 months of treatment?
  3. Did the patient have a clinical relapse with at least one T2 or mRI lesion during the first 6 months of treatment?

Dr. Cascione presented the following results:

  • People who had disability progression within the first 6 months were more likely to have disability progression at 2 and 4 years. This was also seen for the patients randomised from placebo.
  • People who had at least one clinical progression within the first 6 months were more likely to have disability progression at 2 and 4 years. This was less clear for the people who received placebo initially.
  • Patients with at least one T2 or mRI lesion during the first 6 months of treatment were more likely to have disability progression at 4 years.

Dr. Cascione considered that the take-home message was that, after starting an effective therapy for  multiple sclerosis, early assessment is essential.

Dr. Cascione is Medical Director at the South Tampa Multiple Sclerosis Center, Florida, USA.

This interview has been recorded at ECTRIMS 2015, October 2015, Barcelona, Spain.